Back to Journals » Vascular Health and Risk Management » Volume 7

Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders

Authors Mingorance C, Rodriguez, Justo ML, de Sotomayor MA, Herrera MD

Published 28 March 2011 Volume 2011:7 Pages 169—176


Review by Single anonymous peer review

Peer reviewer comments 3

Carmen Mingorance, Rosalía Rodríguez-Rodríguez, María Luisa Justo, María Álvarez de Sotomayor, María Dolores Herrera
Department of Pharmacology, School of Pharmacy, University of Seville, Seville, Spain

Abstract: Acetyl-L-carnitine (ALC) and propionyl-L-carnitine (PLC) are two naturally occurring carnitine derivates formed by carnitine acetyltransferase. The beneficial cardiovascular effects of ALC and PLC have been extensively evaluated in animals and humans during the last 20 years. For instance, many clinical trials have suggested ALC and PLC as potential strategies in the management of peripheral arterial disease, heart and cerebral ischemia, and congestive heart failure. As a result, several experts have already aimed to revise the clinical evidence supporting the therapeutic use of ALC and PLC. On the basis of their conclusions, our aim was a critical review of the effectiveness of ALC and PLC in the treatment of cardiovascular diseases. Type 2 diabetes mellitus is an independent risk factor for the development of cardiovascular disease. Therefore we also describe recent studies that have addressed the emerging use of ALC and PLC amelioration of the insulin resistant state and its related morbidities.

Keywords: propionyl-L-carnitine, acetyl-L-carnitine, L-carnitine, cardiovascular diseases, insulin resistance


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.